PillPrazosin Hydrochloride
Prazosin Hydrochloride
30 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 65 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it30 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 29 | SUPPLYING |
| Asclemed USA, Inc. | unknown | 18 | SUPPLYING |
| Alembic Pharmaceuticals Limited | unknown | 18 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | unknown | 16 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | unknown | 13 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 13 | SUPPLYING |
| Novadoz Pharmaceuticals LLC | unknown | 10 | SUPPLYING |
| ANI Pharmaceuticals, Inc. | unknown | 10 | SUPPLYING |
| Proficient Rx LP | unknown | 7 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | unknown | 7 | SUPPLYING |
| Lifestar Pharma LLC | unknown | 6 | SUPPLYING |
| Exelan Pharmaceuticals, Inc. | unknown | 6 | SUPPLYING |
| Aurobindo Pharma Limited | unknown | 6 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | unknown | 6 | SUPPLYING |
| Marlex Pharmaceuticals Inc | unknown | 6 | SUPPLYING |
+ 15 more labelers
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 27, 2026RECALLRecall (Class II): Prazosin Hydrochloride Capsules, USP, 5mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ,…
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
- Mar 27, 2026RECALLRecall (Class II): Prazosin Hydrochloride Capsules, USP, 2mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ…
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
- Mar 27, 2026RECALLRecall (Class II): Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ,…
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
- Oct 16, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx only, Distributed by American Health Packagi…
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
- Oct 16, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Pack…
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
- Oct 16, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Pack…
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
- Oct 7, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19…
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
- Oct 7, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19…
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
- Oct 7, 2025RECALLRecall (Class II): Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19…
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
- Apr 13, 2022RECALLRecall (Class II): Prazosin Hydrochloride Capsules, USP, 1 mg, 100-count bottle, Rx only, MFG: Mylan Pharma, NDC 0378-1101-01
cGMP deviations: Temperature abuse — Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office — USA nationwide.